IL209849A0 - Sclerostin and the inhibition of wnt signaling and bone formation - Google Patents

Sclerostin and the inhibition of wnt signaling and bone formation

Info

Publication number
IL209849A0
IL209849A0 IL209849A IL20984910A IL209849A0 IL 209849 A0 IL209849 A0 IL 209849A0 IL 209849 A IL209849 A IL 209849A IL 20984910 A IL20984910 A IL 20984910A IL 209849 A0 IL209849 A0 IL 209849A0
Authority
IL
Israel
Prior art keywords
sclerostin
inhibition
bone formation
wnt signaling
wnt
Prior art date
Application number
IL209849A
Original Assignee
Enzo Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzo Biochem Inc filed Critical Enzo Biochem Inc
Publication of IL209849A0 publication Critical patent/IL209849A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
IL209849A 2005-03-18 2010-12-08 Sclerostin and the inhibition of wnt signaling and bone formation IL209849A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/084,668 US8461155B2 (en) 2003-09-22 2005-03-18 Sclerostin and the inhibition of WNT signaling and bone formation
PCT/US2006/009697 WO2006102070A2 (en) 2005-03-18 2006-03-17 Sclerostin and the inhibition of wnt signaling and bone formation

Publications (1)

Publication Number Publication Date
IL209849A0 true IL209849A0 (en) 2011-02-28

Family

ID=37024416

Family Applications (4)

Application Number Title Priority Date Filing Date
IL186010A IL186010A0 (en) 2005-03-18 2007-09-17 Sclerostin and the inhibition of wnt signaling and bone formation
IL209849A IL209849A0 (en) 2005-03-18 2010-12-08 Sclerostin and the inhibition of wnt signaling and bone formation
IL209850A IL209850A0 (en) 2005-03-18 2010-12-08 Sclerostin and the inhibition of wnt signaling and bone formation
IL209848A IL209848A0 (en) 2005-03-18 2010-12-08 Sclerostin and the inhibition of wnt signaling and bone formation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL186010A IL186010A0 (en) 2005-03-18 2007-09-17 Sclerostin and the inhibition of wnt signaling and bone formation

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL209850A IL209850A0 (en) 2005-03-18 2010-12-08 Sclerostin and the inhibition of wnt signaling and bone formation
IL209848A IL209848A0 (en) 2005-03-18 2010-12-08 Sclerostin and the inhibition of wnt signaling and bone formation

Country Status (7)

Country Link
US (4) US8461155B2 (en)
EP (1) EP1883418A4 (en)
JP (1) JP4993623B2 (en)
CN (1) CN101888849A (en)
CA (3) CA2601360C (en)
IL (4) IL186010A0 (en)
WO (1) WO2006102070A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032773A1 (en) 1998-11-27 2000-06-08 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
JP4688802B2 (en) 2003-06-16 2011-05-25 セルテック アール アンド ディー， インコーポレイテッド Sclerostin specific antibodies and methods for increasing bone mineralization
US20100041599A1 (en) * 2006-11-14 2010-02-18 Dakai Liu Compositions and methods for bone formation, bone remodeling and toxin protection
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US8343922B2 (en) * 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP3345607B1 (en) * 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
WO2008092894A1 (en) * 2007-02-02 2008-08-07 Novartis Ag Modulators of sclerostin binding partners for treating bone-related disorders
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
TWI489993B (en) 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin
WO2009079471A1 (en) * 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
US8716243B2 (en) * 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
SG185465A1 (en) 2010-05-14 2012-12-28 Amgen Inc High concentration antibody formulations
US9493541B2 (en) 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
US11167011B2 (en) 2010-06-07 2021-11-09 Enzo Biochem, Inc. Methods for treating bone loss using sclerostin peptides
US9403882B2 (en) 2010-06-07 2016-08-02 Joshua Rabbani Sulfation of Wnt pathway proteins
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
KR20180129991A (en) 2010-11-05 2018-12-05 노파르티스 아게 Methods of treating rheumatoid arthritis using il-17 antagonists
EA201391248A1 (en) 2011-03-01 2014-05-30 Эмджен Инк. BISPECIFIC BINDING AGENTS
EA029956B1 (en) 2011-03-25 2018-06-29 Эмджен Инк. Anti-sclerostin antibody crystals and formulations thereof
EP2702408A1 (en) 2011-04-29 2014-03-05 Novartis AG Methods of treating squamous cell carcinoma related applications
ES2667554T3 (en) 2011-08-04 2018-05-11 Amgen Inc. Method for the treatment of bone space defects
WO2013067355A1 (en) * 2011-11-04 2013-05-10 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
BR112014016108A2 (en) 2011-12-28 2018-09-11 Amgen Inc alvelar bone loss treatment method
EP3626267A1 (en) 2012-07-05 2020-03-25 UCB Pharma, S.A. Treatment for bone diseases
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
JP6796059B2 (en) 2014-09-12 2020-12-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー WNT signaling agonist molecule
MA41142A (en) 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
JP2020502218A (en) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN106709272B (en) * 2016-12-26 2019-07-02 西安石油大学 Method and system based on decision template prediction drug target protein interaction relationship
US20200179510A1 (en) * 2017-03-24 2020-06-11 Yale University Low density lipoprotein receptor related protein 5 inhibition suppresses tumor formation
KR20200011933A (en) 2017-05-31 2020-02-04 베링거 인겔하임 인터내셔날 게엠베하 Polypeptides that antagonize WNT signaling in tumor cells
EP3415527A1 (en) 2017-06-14 2018-12-19 Technische Universität Dresden Use of the extracellular domain of the transferrin receptor 2 for diagnosis and treatment of primary and secondary sclerosing diseases
WO2019126401A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
WO2019126398A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
MX2020010092A (en) 2018-03-30 2020-10-28 Amgen Inc C-terminal antibody variants.
CA3100818A1 (en) * 2018-06-13 2019-12-19 Kymab Limited Treatments etc
JP2023521356A (en) * 2020-04-07 2023-05-24 アドヴァンスド セル ダイアグノスティクス，インコーポレイテッド Method and kit for detecting target nucleic acid by in situ hybridization
CN113354724A (en) * 2021-04-28 2021-09-07 蒋青 Sclerostin and application thereof in preparation of related products for treating or preventing Alzheimer's disease
CN114446392B (en) * 2022-01-21 2024-01-30 华东理工大学 Method for confirming key essential amino acid residue site of protein combined with aptamer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5642292A (en) * 1992-03-27 1997-06-24 Akiko Itai Methods for searching stable docking models of biopolymer-ligand molecule complex
EP0639889B1 (en) * 1993-08-19 1999-09-15 Advanced Micro Devices, Inc. Low voltage fully differential operational amplifiers
US7244577B2 (en) * 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
DE19747418C1 (en) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor protein of the wnt signaling pathway
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2000032773A1 (en) * 1998-11-27 2000-06-08 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
US7369946B2 (en) * 2000-03-29 2008-05-06 Abbott Gmbh & Co. Kg Method of identifying inhibitors of Tie-2
AU5623801A (en) * 2000-03-29 2001-10-08 Max Planck Gesellschaft 3d structure of polypeptides containing a tpr-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said peptides
US20020138204A1 (en) * 2000-08-21 2002-09-26 Mohammad Afshar Computer based modelling system
US7713526B2 (en) * 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
EP1446114A4 (en) * 2001-11-08 2005-05-25 Merck & Co Inc Compositions and methods for treating osteoporosis
EP1575481A4 (en) * 2002-03-01 2010-01-06 Celltech R & D Inc Methods to increase or decrease bone density
US7893218B2 (en) * 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
MXPA05009805A (en) * 2003-03-14 2006-04-18 Celltech R & D Inc Ligands for tgf-beta binding proteins and uses thereof.
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
JP4688802B2 (en) * 2003-06-16 2011-05-25 セルテック アール アンド ディー， インコーポレイテッド Sclerostin specific antibodies and methods for increasing bone mineralization
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US8343922B2 (en) * 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
US20060052943A1 (en) * 2004-07-28 2006-03-09 Karthik Ramani Architectures, queries, data stores, and interfaces for proteins and drug molecules
US7709611B2 (en) * 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
US7838252B2 (en) * 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP3345607B1 (en) * 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
BRPI0809026A2 (en) * 2007-03-20 2014-09-23 Lilly Co Eli ANTIESCLEROTINE ANTIBODIES
TWI489993B (en) * 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin

Also Published As

Publication number Publication date
IL209850A0 (en) 2011-02-28
IL209848A0 (en) 2011-07-31
CA2929206A1 (en) 2006-09-28
US8461155B2 (en) 2013-06-11
IL186010A0 (en) 2008-01-20
CN101888849A (en) 2010-11-17
CA2601360A1 (en) 2006-09-28
JP4993623B2 (en) 2012-08-08
CA2601360C (en) 2013-07-02
JP2008536816A (en) 2008-09-11
WO2006102070A2 (en) 2006-09-28
US20100074891A1 (en) 2010-03-25
EP1883418A2 (en) 2008-02-06
US20120115787A9 (en) 2012-05-10
US20060030523A1 (en) 2006-02-09
EP1883418A4 (en) 2012-09-12
CA2814267A1 (en) 2006-09-28
US20110086021A1 (en) 2011-04-14
WO2006102070A3 (en) 2009-04-23
US20130251735A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
IL209849A0 (en) Sclerostin and the inhibition of wnt signaling and bone formation
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
IL186400A0 (en) Compositions and methods for the inhibition of dishevelled proteins
MX286273B (en) Compositions and methods for inhibition of the jak pathway.
AP2870A (en) Odcase inhibitors for the treatment of malaria
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
GB0718972D0 (en) Compounds and methods of making the compounds
ZA200707472B (en) Diosmetin derivatives for the treatment and prevention of thrombotic pathologies
IL189659A0 (en) Ikk inhibitors for the treatment of endometriosis
EP1858325A4 (en) Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
EP1945261A4 (en) Compositions and methods for controlling tissue factor signaling specificity
IL192025A0 (en) Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
EP1817441A4 (en) Methods of preventing corrosion
ZA200710206B (en) Compositions and methods for inhibition of the JAK path-way
EP1898940A4 (en) Inhibitors of the alpha2beta 1/gpia-iia integrin
EP1742961A4 (en) Inhibition of fgf signaling
GB2432154B (en) Corrosion inhibition
EP1931370A4 (en) Use of des-aspartate-angiotensin i
ZA200607681B (en) Treatment of water
GB0602857D0 (en) The treatment of sialorrhoea
EP1954817A4 (en) Kifs as modifiers of the rho pathway and methods of use
GB0508843D0 (en) Inhibition or treatment of dyskinesia
GB0503540D0 (en) Inhibition or treatment of dyskinesia
TJ20050863A (en) The way of narcotism treatment